Format

Send to

Choose Destination
Cancer Invest. 2017 Nov 26;35(10):625-632. doi: 10.1080/07357907.2017.1408814.

Quantification of Plasma Cell-Free Circulating DNA at Different Stages of Colorectal Cancer.

Author information

1
a Colorectal Research Center , Iran University of Medical Sciences , Tehran , Iran.
2
b Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital , Iran University of Medical Sciences , Tehran , Iran.
3
c Department of Zoology, Faculty of Natural Sciences , University of Tabriz , Tabriz , Iran.

Abstract

Cell-free circulating DNAs (cfcDNAs) have been recognized as promising biomarkers for a number of cancers. This study aimed to quantify the cfcDNA in colorectal cancer to assess its potential value as biomarker. Quantification of baseline cfcDNA was determined as the amount of free glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in plasma, using quantitative real-time polymerase chain reaction (PCR). The calculated area under the curve (AUC) of receiver operating characteristic (ROC) for cfcDNA was 0.875 (95% CI, 0.811-0.94), which was indicative of a high discriminatory power (p < 0.001) and significant accuracy in distinguishing cancer patients from healthy individuals. The quantification of cfcDNA could be useful for clinical settings of CRC.

KEYWORDS:

Biomarker; Blood; Circulating DNA; Colorectal cancer; Plasma

PMID:
29243990
DOI:
10.1080/07357907.2017.1408814
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center